Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Events

26 Oct 2026 - 29 Oct 2026
16 Nov 2026 - 19 Nov 2026

Ovary Removal Cuts Breast Cancer Mortality Risk

By HospiMedica International staff writers
Posted on 06 May 2015
Women with BRCA-positive breast cancer had a significantly lower risk of dying after prophylactic bilateral oophorectomy, according to a new study.

Researchers at McGill University (Montreal, Canada), the Women’s College Research Institute (WCRI; Toronto, ON, Canada), and another 12 institutions conducted a retrospective study of 676 women with stage I or II breast cancer and a BRCA1 or BRCA2 mutation, followed for up to 20 years (after receiving a diagnosis between 1975 and 2008) to estimate the impact of oophorectomy on survival. More...
Survival experience was compared for women who did and who did not undergo oophorectomy, with the primary endpoint being death due to breast cancer.

In all, out of the 676 women, 345 underwent oophorectomy after the diagnosis of breast cancer, while 331 retained both ovaries. The results showed that the magnitude of benefit for ovary removal was 43% for carriers of BRCA2 carriers, and 62% for carriers of BRCA1. Risk reduction jumped to 93% for estrogen receptor-negative breast cancers, which account for a majority of BRCA1-positive breast cancers. The study was published early online on April 23, 2015, in JAMA Oncology.

“In this study, we confirm that women with breast cancer and a BRCA1 mutation improve their prognosis if they undergo oophorectomy, and that the protective effect of the oophorectomy persists beyond age 50 years,” said lead author Steven Narod, MD, of WCRI, and colleagues. “In previous studies, we have shown that oophorectomy reduces the risk of both ovarian and breast cancers, and we now report that the benefits of oophorectomy include a reduction in the risk of breast cancer mortality.”

The risk of developing breast and ovarian cancer is greatly increased if a woman inherits a mutation in the BRCA1 or BRCA2 gene, which produces tumor suppressor proteins. Together, BRCA1 and BRCA2 mutations account for about 20%–25% percent of hereditary breast cancers, and about 5%–10% of all breast cancers. Several study groups have recommended prophylactic salpingo-oophorectomy for BRCA carriers at age 35 or older to reduce the risk of breast and ovarian cancer.

Related Links:

McGill University
Women’s College Research Institute




Gold Member
Blood Gas Analyzer
i-Check200
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Monitor/Defibrillator
Zenix
Gas Analyzer
GE SAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image:The NCIBT team with the cath lab members celebrating the completion of the study. (Image Credit: UC Davis)

Dual-Imaging Catheter Completes Initial Human Evaluation of Coronary Plaque

Atherosclerosis involves plaque buildup in arterial walls that can narrow blood vessels and increase the risk of heart attack, stroke, and other serious cardiovascular conditions. In coronary arteries,... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.